David Foehr Sells 993 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 993 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $23,851.86. Following the completion of the transaction, the vice president directly owned 36,758 shares of the company’s stock, valued at $882,927.16. The trade was a 2.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The shares were sold at an average price of $23.95, for a total transaction of $20,573.05.

CeriBell Price Performance

Shares of CBLL opened at $23.45 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The company’s fifty day moving average price is $19.89 and its 200-day moving average price is $19.30. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33. The firm has a market capitalization of $900.01 million, a PE ratio of -13.32 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, equities research analysts predict that CeriBell, Inc. will post -1.96 EPS for the current year.

Institutional Trading of CeriBell

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in CeriBell in the 2nd quarter valued at $37,657,000. Bank of New York Mellon Corp raised its position in CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after acquiring an additional 1,162,200 shares during the period. KCM Capital Inc purchased a new position in CeriBell during the fourth quarter valued at $21,930,000. TimesSquare Capital Management LLC purchased a new position in CeriBell in the 2nd quarter valued at about $15,182,000. Finally, Royce & Associates LP purchased a new stake in CeriBell during the 4th quarter worth approximately $11,695,000.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CBLL. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Canaccord Genuity Group increased their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, BTIG Research raised their target price on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.40.

CeriBell News Roundup

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG Research raised its price target for CBLL to $30 from $28 and reiterated a Buy rating. Canaccord Genuity also increased its target to $26, while the overall analyst consensus remains “Moderate Buy.”
• Positive Sentiment: Several institutional investors recently increased or initiated positions in CeriBell, including Caitong International Asset Management, CWM LLC, Tower Research Capital and Legal & General, although the dollar values of these holdings remain modest.
• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares worth about $307,000. The executives retained substantial positions, and the filings identified tax withholding after equity vesting as the reason for the sales. CeriBell insider transaction report
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from August 10. The zero-day days-to-cover figure offers little useful information and may reflect anomalous reporting.
• Negative Sentiment: CeriBell’s latest quarterly results were mixed: revenue of $28.10 million exceeded expectations, but adjusted earnings of negative $0.51 per share missed the consensus estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss of approximately $1.96 per share.
• Negative Sentiment: The coordinated selling by multiple senior executives may create a modest overhang, particularly with the shares near their 52-week high. The impact is tempered by the sales’ stated tax-related purpose and the executives’ continued ownership.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.